Juliana Marques Sá
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juliana Marques Sá has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Maria Joana Santos
2 shared publications- Maria Joana Santos
Serviço de Endocrinologia do Hospital de Braga, Braga, Portugal
2 shared publications - Mariana Barbosa
Endocrinology Department, Braga Hospital, Braga, Portugal
2 shared publications - Sara Campos Lopes
Endocrinology Department, Hospital de Braga, Braga, Portugal
2 shared publications - Adriana De Sousa Lages
Department of Endocrinology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
1 shared publication Ana Sofia Correia
1 shared publication
Latest Publications
- Open Access
- 29 July 2025
- Published by S. Karger AG in Endocrinology Insights
- Vol. 20 (3) , 157-164
Prader-Willi Syndrome Diagnosis in Adulthood: A Case Report
Introduction: The Prader-Willi syndrome is a rare complex multisystem genetic disorder characterized by neonatal hypotonia and feeding difficulties in early infancy, cognitive impairment, psychiatric disease, and multiple dysmorphic features. Hypothalamic dysfunction is the main endocrinological complication, leading to hyperphagia, with severe obesity and hypopituitarism, among other abnormalities. Even though manifestations are present from birth, affected individuals can remain undiagnosed until adulthood. Case Presentation: In this case, we described a 40-year-old woman with cognitive impairment and previously diagnosed hypothyroidism, referred to endocrinology due to morbid obesity, insatiable appetite, and food voracity. She reported menarche after the age of 20, oligomenorrhea and recurrent episodes of asthenia, lethargy, and hypothermia, especially when she had respiratory infections. On physical examination, she had short stature, almond-shaped eyes, thin upper lip, lip inversion, small hands, and centripetal obesity. Her lab tests showed normal free-T4 levels under levothyroxine, low morning serum cortisol, and low IGF-1. Pituitary magnetic resonance showed a small pituitary gland. The diagnosis of hypopituitarism was established, and she started prednisolone, with resolution of the lethargy and hypothermia episodes and improvement of her general condition. Prader-Willi syndrome was suspected and confirmed by a genetic test. Conclusion: This case highlights the importance of the physician to be attentive to the patient at each consultation, taking a holistic view of the patient, and avoid assuming their previous diagnoses as definitive. Furthermore, this case draws attention to the delayed diagnosis of a genetic syndrome, despite the patient having received specialized care at a tertiary center.
- 29 July 2025
- Published by S. Karger AG in Endocrinology Insights
- Vol. 20 (3) , 157-164
Open AccessPrader-Willi Syndrome Diagnosis in Adulthood: A Case Report
Introduction: The Prader-Willi syndrome is a rare complex multisystem genetic disorder characterized by neonatal hypotonia and feeding difficulties in early infancy, cognitive impairment, psychiatric disease, and multiple dysmorphic features. Hypothalamic dysfunction is the main endocrinological complication, leading to hyperphagia, with severe obesity and hypopituitarism, among other abnormalities. Even though manifestations are present from birth, affected individuals can remain undiagnosed until adulthood. Case Presentation: In this case, we described a 40-year-old woman with cognitive impairment and previously diagnosed hypothyroidism, referred to endocrinology due to morbid obesity, insatiable appetite, and food voracity. She reported menarche after the age of 20, oligomenorrhea and recurrent episodes of asthenia, lethargy, and hypothermia, especially when she had respiratory infections. On physical examination, she had short stature, almond-shaped eyes, thin upper lip, lip inversion, small hands, and centripetal obesity. Her lab tests showed normal free-T4 levels under levothyroxine, low morning serum cortisol, and low IGF-1. Pituitary magnetic resonance showed a small pituitary gland. The diagnosis of hypopituitarism was established, and she started prednisolone, with resolution of the lethargy and hypothermia episodes and improvement of her general condition. Prader-Willi syndrome was suspected and confirmed by a genetic test. Conclusion: This case highlights the importance of the physician to be attentive to the patient at each consultation, taking a holistic view of the patient, and avoid assuming their previous diagnoses as definitive. Furthermore, this case draws attention to the delayed diagnosis of a genetic syndrome, despite the patient having received specialized care at a tertiary center.
- Open Access
- 7 March 2025
- Published by S. Karger AG in Endocrinology Insights
- Vol. 20 (2) , 75-82
Graves’ Disease before and after the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: Experience of a Clinical Center
Introduction: New cases of Graves’ disease (GD) have been reported in association with SARS-CoV-2 infection and vaccination. We aimed to determine if there was an increase in the new cases of GD after the SARS-CoV-2 pandemic, to compare the characteristics of GD patients before and after the pandemic, and to compare GD patients’ characteristics in relation to the presence of SARS-CoV-2 infection and/or vaccination. Methods: Retrospective and observational study evaluating sociodemographic, analytical, and treatment-related characteristics of newly diagnosed GD patients, who had their first consultation at the Endocrinology Department of Hospital de Braga between 2018 and 2022 (GDbP: pre-pandemic symptoms; GDaP: post-pandemic symptoms). GDaP was subdivided into four subgroups (GDnIV, GDwI, GDwV, and GDwIV) based on SARS-CoV-2 infection (I) and/or vaccination (V). Results: We included 250 patients: 108 (43.2%) in the GDbP group and 142 (56.8%) in the GDaP group. There was a significant increase in the first endocrinology appointments due to GD after the pandemic (2.85% vs 5.11%, p < 0.001). When compared to GDbP, GDaP took less time to start (p < 0.05), reduce dosage (p < 0.05), and discontinue medical treatment (p < 0.05). Compared to the GDbP group, the GDwI subgroup showed higher anti-Tg levels (p < 0.05); the GDnIV, GDwV, and GDwIV subgroups took less time to initiate and discontinue medical treatment (p < 0.05). GDwI and GDwV patients had higher free thyroxine (FT4) levels than the GDnIV group (p < 0.05). GDwV patients took less time to reduce medical treatment dose compared to GDnIV (p < 0.05). Conclusions: There was an increase in the number of new GD cases with the SARS-CoV-2 pandemic. These patients took less time to initiate, reduce, and discontinue medical treatment. Some subgroups with GD related to I and V showed higher FT4 and anti-Tg titers when compared to pre-pandemic GD patients or GD with no relation to SARS-CoV-2 infection or vaccination.
- 7 March 2025
- Published by S. Karger AG in Endocrinology Insights
- Vol. 20 (2) , 75-82
Open AccessGraves’ Disease before and after the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: Experience of a Clinical Center
Introduction: New cases of Graves’ disease (GD) have been reported in association with SARS-CoV-2 infection and vaccination. We aimed to determine if there was an increase in the new cases of GD after the SARS-CoV-2 pandemic, to compare the characteristics of GD patients before and after the pandemic, and to compare GD patients’ characteristics in relation to the presence of SARS-CoV-2 infection and/or vaccination. Methods: Retrospective and observational study evaluating sociodemographic, analytical, and treatment-related characteristics of newly diagnosed GD patients, who had their first consultation at the Endocrinology Department of Hospital de Braga between 2018 and 2022 (GDbP: pre-pandemic symptoms; GDaP: post-pandemic symptoms). GDaP was subdivided into four subgroups (GDnIV, GDwI, GDwV, and GDwIV) based on SARS-CoV-2 infection (I) and/or vaccination (V). Results: We included 250 patients: 108 (43.2%) in the GDbP group and 142 (56.8%) in the GDaP group. There was a significant increase in the first endocrinology appointments due to GD after the pandemic (2.85% vs 5.11%, p < 0.001). When compared to GDbP, GDaP took less time to start (p < 0.05), reduce dosage (p < 0.05), and discontinue medical treatment (p < 0.05). Compared to the GDbP group, the GDwI subgroup showed higher anti-Tg levels (p < 0.05); the GDnIV, GDwV, and GDwIV subgroups took less time to initiate and discontinue medical treatment (p < 0.05). GDwI and GDwV patients had higher free thyroxine (FT4) levels than the GDnIV group (p < 0.05). GDwV patients took less time to reduce medical treatment dose compared to GDnIV (p < 0.05). Conclusions: There was an increase in the number of new GD cases with the SARS-CoV-2 pandemic. These patients took less time to initiate, reduce, and discontinue medical treatment. Some subgroups with GD related to I and V showed higher FT4 and anti-Tg titers when compared to pre-pandemic GD patients or GD with no relation to SARS-CoV-2 infection or vaccination.
- Open Access
- 26 February 2024
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e230055
Multiple basal infusion rates in open-loop insulin delivery systems: is there a metabolic benefit?
Objective: To evaluate glycemic control according to the number of daily basal rates (BRs) in type 1 diabetes patients using continuous subcutaneous insulin infusion (CSII). Subjects and methods: Cross-sectional study of patients treated with an open-loop CSII for at least 6 months and using a flash glucose monitoring system. Patients were divided into 2 groups: group 1 (G1) and group 2 (G2), with ≤4 and >4 BRs/24h, respectively. The groups were compared regarding HbA1c, time in range (TIR), time [...] ABSTRACT Objective: To evaluate glycemic control according to the number of daily basal rates (BRs) in type 1 diabetes patients using continuous subcutaneous insulin infusion (CSII). Subjects and methods: Cross-sectional study of patients treated with an open-loop CSII for at least 6 months and using a flash glucose monitoring system. Patients were divided into 2 groups: group 1 (G1) and group 2 (G2), with ≤4 and >4 BRs/24h, respectively. The groups were compared regarding HbA1c, time in range (TIR), time
- 26 February 2024
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e230055
Open AccessMultiple basal infusion rates in open-loop insulin delivery systems: is there a metabolic benefit?
Objective: To evaluate glycemic control according to the number of daily basal rates (BRs) in type 1 diabetes patients using continuous subcutaneous insulin infusion (CSII). Subjects and methods: Cross-sectional study of patients treated with an open-loop CSII for at least 6 months and using a flash glucose monitoring system. Patients were divided into 2 groups: group 1 (G1) and group 2 (G2), with ≤4 and >4 BRs/24h, respectively. The groups were compared regarding HbA1c, time in range (TIR), time [...] ABSTRACT Objective: To evaluate glycemic control according to the number of daily basal rates (BRs) in type 1 diabetes patients using continuous subcutaneous insulin infusion (CSII). Subjects and methods: Cross-sectional study of patients treated with an open-loop CSII for at least 6 months and using a flash glucose monitoring system. Patients were divided into 2 groups: group 1 (G1) and group 2 (G2), with ≤4 and >4 BRs/24h, respectively. The groups were compared regarding HbA1c, time in range (TIR), time
- Open Access
- 21 June 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (6) , e000649
Is elevated blood glucose at admission associated with poor outcomes in hospitalized COVID-19 patients?
Objective: Hyperglycemia has been suggested as a risk factor for poor outcomes in coronavirus disease 2019 (COVID-19). The aim of our work was to evaluate the association between blood glucose levels at admission (BGA) and disease outcomes in hospitalized COVID-19 patients. Subjects and methods: Retrospective study including all adult COVID-19 patients admitted to a Portuguese hospital from March to August 2020 with BGA measurement. Subjects were categorized into two groups: BGA < 140 mg/dL and ≥ 140 mg/dL. Statistical
- 21 June 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (6) , e000649
Open AccessIs elevated blood glucose at admission associated with poor outcomes in hospitalized COVID-19 patients?
Objective: Hyperglycemia has been suggested as a risk factor for poor outcomes in coronavirus disease 2019 (COVID-19). The aim of our work was to evaluate the association between blood glucose levels at admission (BGA) and disease outcomes in hospitalized COVID-19 patients. Subjects and methods: Retrospective study including all adult COVID-19 patients admitted to a Portuguese hospital from March to August 2020 with BGA measurement. Subjects were categorized into two groups: BGA < 140 mg/dL and ≥ 140 mg/dL. Statistical
- Open Access
- 30 September 2021
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 65 (5) , 640-647
Flash glucose monitoring system: impact on glycemic control and body mass index in type 1 diabetes mellitus
Objective: Flash glucose monitoring (FGM) is increasingly used in type 1 diabetes mellitus (T1D) management. This study aimed to assess glycated hemoglobin (HbA1c) and body mass index (BMI) in the first year of FGM use in patients with T1D and to identify predictive factors of benefit associated with its use. Subjects and methods: Retrospective study of T1D patients, using FGM for ≥ 6 months and under intensive insulin therapy with multiple daily injections. Results: In 179 patients with a [...] ABSTRACT Objective: Flash glucose monitoring (FGM) is increasingly used in type 1 diabetes mellitus (T1D) management. This study aimed to assess glycated hemoglobin (HbA1c) and body mass index (BMI) in the first year of FGM use in patients with T1D and to identify predictive factors of benefit associated with its use. Subjects and methods: Retrospective study of T1D patients, using FGM for ≥ 6 months and under intensive insulin therapy with multiple daily injections. Results: In 179 patients with a
- 30 September 2021
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 65 (5) , 640-647
Open AccessFlash glucose monitoring system: impact on glycemic control and body mass index in type 1 diabetes mellitus
Objective: Flash glucose monitoring (FGM) is increasingly used in type 1 diabetes mellitus (T1D) management. This study aimed to assess glycated hemoglobin (HbA1c) and body mass index (BMI) in the first year of FGM use in patients with T1D and to identify predictive factors of benefit associated with its use. Subjects and methods: Retrospective study of T1D patients, using FGM for ≥ 6 months and under intensive insulin therapy with multiple daily injections. Results: In 179 patients with a [...] ABSTRACT Objective: Flash glucose monitoring (FGM) is increasingly used in type 1 diabetes mellitus (T1D) management. This study aimed to assess glycated hemoglobin (HbA1c) and body mass index (BMI) in the first year of FGM use in patients with T1D and to identify predictive factors of benefit associated with its use. Subjects and methods: Retrospective study of T1D patients, using FGM for ≥ 6 months and under intensive insulin therapy with multiple daily injections. Results: In 179 patients with a